Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Everest Medicines Ltd. ( (HK:1952) ) is now available.
Everest Medicines Ltd. has announced that its Annual General Meeting (AGM) will be held virtually on June 27, 2025. Key agenda items include the adoption of the company’s financial statements for 2024, re-election of executive directors, re-appointment of Ernst & Young as auditors, and granting of mandates to repurchase shares and issue additional shares. These resolutions aim to strengthen the company’s governance and operational flexibility, potentially enhancing its market position and shareholder value.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in Asia and other emerging markets. The company specializes in innovative therapies across various therapeutic areas, including oncology, autoimmune disorders, cardio-renal diseases, and infectious diseases.
Average Trading Volume: 5,331,989
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.94B
Learn more about 1952 stock on TipRanks’ Stock Analysis page.